Brazil
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2013 200 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.4 (2.5–6.8) 2.2 (1.3–3.4)
Mortality (HIV+TB only) 2.1 (1.5–2.7) 1 (0.77–1.4)
Prevalence  (includes HIV+TB) 110 (54–200) 57 (27–99)
Incidence  (includes HIV+TB) 93 (83–110) 46 (41–52)
Incidence (HIV+TB only) 13 (13–13) 6.5 (6.5–6.6)
Case detection, all forms (%) 82 (72–92)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.4 (1–1.8) 7.5 (5.7–9.9)
MDR-TB cases among notified pulmonary
TB cases
840 (600–1 100) 940 (710–1 200)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 41 885   3 613
Pulmonary, clinically diagnosed 18 303   1 604
Extrapulmonary 10 148   467
       
Total new and relapse 76 020    
Previously treated, excluding relapses 7 290    
Total cases notified 83 310    
Among 76 020 new and relapse cases:
2 647 (3%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 670 (2%) 217 (2%) 895
Laboratory-confirmed RR-/MDR-TB cases     706
Patients started on MDR-TB treatment     717
TB/HIV 2013 Number (%)
TB patients with known HIV status 54 213 (65)
HIV-positive TB patients 9 340 (17)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 72
Previously treated cases, excluding relapse, registered in 2012 36
HIV-positive TB cases, all types, registered in 2012 48
RR-/MDR-TB cases started on second-line treatment in 2011 56
XDR-TB cases started on second-line treatment in 2011 21
Laboratories 2013  
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 8.4
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 79
% Funded domestically 87%
% Funded internationally 2%
% Unfunded 12%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-02 Data: www.who.int/tb/data